ATM and brain cancer: Recently, a Phase I clinical trial investigating the radiosensitizing efficiency of M3541, a selective inhibitor of ATM, has closed unsuccessfully (Waqar et al., 2022), while another, assessing the safety and tolerability of the ATM inhibitor AZD1390 in combination to RT in patients with brain cancer is ongoing (NCT03423628).